Under these conditions TGFβ treatment results in a reduced expression of genes which contribute to adipogenic differentiation, including PPARG, ADAMTS5, and AKR1B10. Since FDA-approved drugs are available for these genes, they are potential targets for treatment of patients suffering from osteoporosis or obesity. This evidence concerns the gene TGFB1 and Obesity.